X0202 SCHEDULE 13G/A 0001104659-26-016660 0001940272 XXXXXXXX LIVE 2 Class A Common Stock, par value $0.0001 per share 06/30/2026 0001637715 OnKure Therapeutics, Inc. 68277Q105 6707 Winchester Circle Suite 400 Boulder CO 80301 Rule 13d-1(b) ADAR1 Capital Management, LLC b TX 0.00 2238684.00 0.00 2238684.00 2238684.00 N 5.5 IA OO Includes (i) 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 299,150 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 107,417 shares of Common Stock held by other separately managed accounts as of June 30, 2026. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026. ADAR1 Capital Management GP, LLC b TX 0.00 1832117.00 0.00 1832117.00 1832117.00 N 4.5 OO Includes 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP as of June 30, 2026. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026. Daniel Schneeberger b TX 0.00 2238684.00 0.00 2238684.00 2238684.00 N 5.5 HC IN Includes (i) 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 299,150 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 107,417 shares of Common Stock held by other separately managed accounts as of June 30, 2026. As the manager of ADAR1 Capital Management, LLC, and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026. OnKure Therapeutics, Inc. 6707 Winchester Circle Suite 400, Boulder, CO 80301 This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); (ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and (iii) Daniel Schneeberger ("Mr. Schneeberger"). Pursuant to Item 5 below, this filing is an exit filing solely for ADAR1 General Partner. The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738. (i) ADAR1 Capital Management is a Texas limited liability company; (ii) ADAR1 General Partner is a Texas limited liability company; and (iii) Mr. Schneeberger is a citizen of Switzerland. N IA HC The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. N Y Y N Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E). Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. ADAR1 Capital Management, LLC /s/ Daniel Schneeberger 08/14/2026 ADAR1 Capital Management GP, LLC /s/ Daniel Schneeberger 08/14/2026 Daniel Schneeberger /s/ Daniel Schneeberger 08/14/2026